PerkinElmer has successfully completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital.
The resulting new Life Sciences and Diagnostics business will share the PerkinElmer name until a new name, brand and ticker symbol is unveiled in Q2 2023 pending shareholder approval.
“Today marks the culmination of the hard work and dedication from PerkinElmer teams around the world to ensure that both new companies are in a position to succeed on day one,” said Prahlad Singh, President and Chief Executive Officer of the PerkinElmer Life Sciences and Diagnostics company.
“I’m looking forward to sharing our new name and brand in the near future.”
Within Life Sciences, the company is focused on supporting pharmaceutical and academic scientific advancement from the earliest stage of discovery. In Diagnostics, the company develops new assays, systems, and complete workflows to help better diagnose disease.